bYoRNA & Dyadic Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
bYoRNA SAS and Dyadic International, Inc. recently announced they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (mRNA). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.
“I am excited to announce this development and commercialization agreement to explore the potential to utilize our C1 protein production platform to produce high-quality messenger RNA products at lower cost which will be easier to manufacture than in vitro mRNA, making it accessible to everyone, including patients from poorer countries. The global mRNA vaccine and therapeutics market was valued at USD 34.7 billion in 2022 and is expected to reach USD 68.1 billion by 2030, making this an extremely valuable potential opportunity for both companies to enter the rapidly expanding market for mRNA-based vaccines and therapies, said Mark Emalfarb, Dyadic’s Chief Executive Officer. “If this collaboration is successful, Dyadic has the potential to receive certain defined milestone and royalty payments from bYoRNA and the ability to obtain a license to the BRNA platform.”
“The COVID-19 pandemic brought mRNA technology to the forefront, showing its potential to prevent and treat diseases. Within this collaboration, we will combine our respective technologies to try to express “bio” RNA from Dyadic’s eukaryotic C1-cells, to design, develop and commercialize messenger RNA products,” said Pascal Viguié, bYoRNA’s Chief Executive Officer.
“We believe that by combining bYoRNA’s novel eukaryotic “bio” RNA platform with Dyadic’s industrially proven C1 protein production platform, we will be able to provide the pharmaceutical industry with a more cost-efficient platform for manufacturing large quantities of lower cost mRNA, enabling access to mRNA vaccines and drugs to a broader global population,” said Thierry Ziegler, bYoRNA’s Chief Technology Officer.
bYoRNA SAS is a French biotechnology company focused on developing a cost-efficient and scalable mRNA bioproduction platform for prophylactic and oncological vaccines. mRNA is currently produced in vitro via enzymatic synthesis, an expensive method. Our bioproduction technology will help mass produce long, GMP-grade mRNA in a cost-efficient and scalable fashion by leveraging processes in engineered living cells.
By bringing down the production cost of mRNA and simplifying the supply chain to make it local and more resilient, bYoRNA will help make mRNA vaccines available to the population of emerging countries. By producing longer, naturally modified mRNA, bYoRNA will contribute to the emergence of novel mRNA-based modalities. For more information, visit https://www.byorna.bio.
Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.
Dyadic’s gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Our lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is currently used to speed development, lower production costs, and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. Dyadic has also developed the Dapibus™ filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, such as food, nutrition, and wellness.
With a passion to enable our partners and collaborators to develop effective preventative and therapeutic treatments in both developed and emerging countries, Dyadic is building an active pipeline by advancing its proprietary microbial platform technologies, including our lead asset DYAI-100 COVID-19 vaccine candidate, as well as other biologic vaccines, antibodies, and other biological products. For more information, visit https://www.dyadic.com.
Total Page Views: 1155